Symbiotec Pharmalab Limited (NSE:SYMBIOTEC)
India · Delayed Price · Currency is INR 1,198.00
+21.25 (1.81%)
At close: Oct 1, 2026
Symbiotec Pharmalab Revenue
Symbiotec Pharmalab had revenue of 2.18B INR in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to 8.84B. In the fiscal year ending March 31, 2026, Symbiotec Pharmalab had annual revenue of 8.69B with 15.65% growth.
Revenue (ttm)
8.84B
Revenue Growth
+15.65%
P/S Ratio
8.71
Revenue / Employee
4.62M
Employees
1,915
Market Cap
76.98B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 8.69B | 1.18B | 15.65% |
| Mar 31, 2025 | 7.52B | 353.07M | 4.93% |
| Mar 31, 2024 | 7.16B | 1.50B | 26.43% |
| Mar 31, 2023 | 5.67B | -1.15B | -16.91% |
| Mar 31, 2022 | 6.82B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 25.24B |
| Neuland Laboratories | 23.72B |
| Shilpa Medicare | 16.83B |
| Bajaj HealthCare | 6.28B |
| NGL Fine-Chem | 5.36B |
| Aarey Drugs & Pharmaceuticals | 4.15B |
| Gujarat Themis Biosyn | 1.74B |
| Influx Healthtech | 1.47B |